BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 29949929)

  • 21. Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma.
    Johnson TG; Schelch K; Cheng YY; Williams M; Sarun KH; Kirschner MB; Kao S; Linton A; Klebe S; McCaughan BC; Lin RCY; Pirker C; Berger W; Lasham A; van Zandwijk N; Reid G
    J Thorac Oncol; 2018 Feb; 13(2):258-272. PubMed ID: 29113949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma.
    Minnema-Luiting J; Vroman H; Aerts J; Cornelissen R
    Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29601534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma.
    Cho H; Matsumoto S; Fujita Y; Kuroda A; Menju T; Sonobe M; Kondo N; Torii I; Nakano T; Lara PN; Gandara DR; Date H; Hasegawa S
    J Thorac Oncol; 2017 Mar; 12(3):477-490. PubMed ID: 27867002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intrapleural Adenoviral-mediated Endothelial Cell Protein C Receptor Gene Transfer Suppresses the Progression of Malignant Pleural Mesothelioma in a Mouse Model.
    Keshava S; Rao LV; Pendurthi UR
    Sci Rep; 2016 Nov; 6():36829. PubMed ID: 27833109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A molecular targeting against nuclear factor-κB, as a chemotherapeutic approach for human malignant mesothelioma.
    Nishikawa S; Tanaka A; Matsuda A; Oida K; Jang H; Jung K; Amagai Y; Ahn G; Okamoto N; Ishizaka S; Matsuda H
    Cancer Med; 2014 Apr; 3(2):416-25. PubMed ID: 24510578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential Susceptibility of Human Pleural and Peritoneal Mesothelial Cells to Asbestos Exposure.
    Dragon J; Thompson J; MacPherson M; Shukla A
    J Cell Biochem; 2015 Aug; 116(8):1540-52. PubMed ID: 25757056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy.
    Watanabe Y; Kojima T; Kagawa S; Uno F; Hashimoto Y; Kyo S; Mizuguchi H; Tanaka N; Kawamura H; Ichimaru D; Urata Y; Fujiwara T
    Oncogene; 2010 Feb; 29(8):1145-54. PubMed ID: 19935710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma.
    Di Marzo D; Forte IM; Indovina P; Di Gennaro E; Rizzo V; Giorgi F; Mattioli E; Iannuzzi CA; Budillon A; Giordano A; Pentimalli F
    Cell Cycle; 2014; 13(4):652-65. PubMed ID: 24345738
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effects of microRNA-106b on migration and invasion of human malignant pleural mesothelioma cell NCI-H2452].
    Gao YN; Zhang M; Zhang FF; Jia ZY; Yuan XY; Zhu LJ
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2023 Sep; 41(9):648-654. PubMed ID: 37805422
    [No Abstract]   [Full Text] [Related]  

  • 30. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
    Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
    Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intratumoral macrophage phenotype and CD8+ T lymphocytes as potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesothelioma.
    Cornelissen R; Lievense LA; Robertus JL; Hendriks RW; Hoogsteden HC; Hegmans JP; Aerts JG
    Lung Cancer; 2015 Jun; 88(3):332-7. PubMed ID: 25843042
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AHNAK is highly expressed and plays a key role in cell migration and invasion in mesothelioma.
    Sudo H; Tsuji AB; Sugyo A; Abe M; Hino O; Saga T
    Int J Oncol; 2014 Feb; 44(2):530-8. PubMed ID: 24253341
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma.
    Kalra N; Zhang J; Thomas A; Xi L; Cheung M; Talarchek J; Burkett S; Tsokos MG; Chen Y; Raffeld M; Miettinen M; Pastan I; Testa JR; Hassan R
    BMC Cancer; 2015 May; 15():376. PubMed ID: 25952750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts.
    De Cesare M; Sfondrini L; Pennati M; De Marco C; Motta V; Tagliabue E; Deraco M; Balsari A; Zaffaroni N
    J Transl Med; 2016 Jan; 14():25. PubMed ID: 26810896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tissue transglutaminase (TG2) enables survival of human malignant pleural mesothelioma cells in hypoxia.
    Zonca S; Pinton G; Wang Z; Soluri MF; Tavian D; Griffin M; Sblattero D; Moro L
    Cell Death Dis; 2017 Feb; 8(2):e2592. PubMed ID: 28151477
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of MIF/CD74 signaling pathway in the development of pleural mesothelioma.
    D'Amato-Brito C; Cipriano D; Colin DJ; Germain S; Seimbille Y; Robert JH; Triponez F; Serre-Beinier V
    Oncotarget; 2016 Mar; 7(10):11512-25. PubMed ID: 26883190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical course of human epithelial-type malignant pleural mesothelioma replicated in an orthotopic-transplant nude mouse model.
    Colt HG; Astoul P; Wang X; Yi ES; Boutin C; Hoffman RM
    Anticancer Res; 1996; 16(2):633-9. PubMed ID: 8687108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pleural Effusions from Patients with Mesothelioma Induce Recruitment of Monocytes and Their Differentiation into M2 Macrophages.
    Chéné AL; d'Almeida S; Blondy T; Tabiasco J; Deshayes S; Fonteneau JF; Cellerin L; Delneste Y; Grégoire M; Blanquart C
    J Thorac Oncol; 2016 Oct; 11(10):1765-73. PubMed ID: 27418105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative genetic analysis of a rare synchronous collision tumor composed of malignant pleural mesothelioma and primary pulmonary adenocarcinoma.
    Naka T; Hatanaka Y; Marukawa K; Okada H; Hatanaka KC; Sakakibara-Konishi J; Oizumi S; Hida Y; Kaga K; Mitsuhashi T; Matsuno Y
    Diagn Pathol; 2016 Apr; 11():38. PubMed ID: 27091358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications.
    Tolani B; Acevedo LA; Hoang NT; He B
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29342862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.